Financials Medios AG

Equities

ILM1

DE000A1MMCC8

Pharmaceuticals

Market Closed - Xetra 16:36:02 28/06/2024 BST 5-day change 1st Jan Change
16.14 EUR -2.89% Intraday chart for Medios AG -3.24% +1.77%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 384.5 601.6 787.3 400.4 377.6 411.7 - -
Enterprise Value (EV) 1 375.1 601 668.6 342.4 324 568.7 521.6 468.7
P/E ratio 40.6 x 95.9 x 105 x 22.7 x 20.1 x 14.1 x 10 x 8.34 x
Yield - - - - - - - -
Capitalization / Revenue 0.74 x 0.96 x 0.58 x 0.25 x 0.21 x 0.2 x 0.19 x 0.18 x
EV / Revenue 0.73 x 0.96 x 0.49 x 0.21 x 0.18 x 0.28 x 0.24 x 0.21 x
EV / EBITDA 22.9 x 39.8 x 17.4 x 6.24 x 5.35 x 6.96 x 5 x 4.03 x
EV / FCF -148 x -14.7 x 13 x 10.7 x 21.4 x 12.6 x 11 x 8.45 x
FCF Yield -0.68% -6.79% 7.72% 9.36% 4.67% 7.93% 9.06% 11.8%
Price to Book 4.71 x 4.22 x 2.26 x 0.93 x 0.81 x 0.84 x 0.78 x 0.72 x
Nbr of stocks (in thousands) 14,564 16,085 20,265 22,881 23,806 25,510 - -
Reference price 2 26.40 37.40 38.85 17.50 15.86 16.14 16.14 16.14
Announcement Date 08/04/20 31/03/21 29/03/22 30/03/23 27/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 516.8 626.5 1,357 1,611 1,785 2,012 2,167 2,260
EBITDA 1 16.37 15.1 38.44 54.88 60.51 81.66 104.4 116.2
EBIT 1 14.39 9.542 15.26 28.97 31.37 52.96 76.06 83.13
Operating Margin 2.78% 1.52% 1.12% 1.8% 1.76% 2.63% 3.51% 3.68%
Earnings before Tax (EBT) 1 14.22 8.901 13.58 27.82 29.37 42.46 65 73.03
Net income 1 9.76 6.064 7.402 18.33 18.81 28.9 44.03 49.41
Net margin 1.89% 0.97% 0.55% 1.14% 1.05% 1.44% 2.03% 2.19%
EPS 2 0.6500 0.3900 0.3700 0.7700 0.7900 1.147 1.610 1.936
Free Cash Flow 1 -2.539 -40.84 51.62 32.06 15.14 45.1 47.28 55.47
FCF margin -0.49% -6.52% 3.8% 1.99% 0.85% 2.24% 2.18% 2.45%
FCF Conversion (EBITDA) - - 134.31% 58.42% 25.03% 55.23% 45.28% 47.74%
FCF Conversion (Net income) - - 697.39% 174.91% 80.51% 156.05% 107.37% 112.26%
Dividend per Share 2 - - - - - - - -
Announcement Date 08/04/20 31/03/21 29/03/22 30/03/23 27/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2024 Q2
Net sales 1 - 368.6 393 399.2 419.2 460
EBITDA 1 18.26 10.23 14.14 14.32 15.3 15.1
EBIT 1 - - - - - 6.8
Operating Margin - - - - - 1.48%
Earnings before Tax (EBT) - - 7.588 - 8.594 -
Net income - - - - - -
Net margin - - - - - -
EPS 2 - - 0.2100 - 0.2500 0.1800
Dividend per Share - - - - - -
Announcement Date 12/08/21 29/03/22 11/05/22 11/08/22 10/11/22 -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 157 110 57
Net Cash position 1 9.38 0.55 119 58 53.6 - - -
Leverage (Debt/EBITDA) - - - - - 1.922 x 1.053 x 0.4904 x
Free Cash Flow 1 -2.54 -40.8 51.6 32.1 15.1 45.1 47.3 55.5
ROE (net income / shareholders' equity) 12.8% 5.41% 2.76% 4.35% 4.1% 5.33% 8.31% 8.95%
ROA (Net income/ Total Assets) - - 2.06% 3.33% 3.21% 4.18% 5.44% 6.4%
Assets 1 - - 359.3 550.1 585.4 692 808.8 772.4
Book Value Per Share 2 5.600 8.850 17.20 18.80 19.70 19.30 20.60 22.40
Cash Flow per Share 2 - - 3.050 1.560 0.6900 1.980 3.210 3.300
Capex 1 2.09 2.72 9.9 5.06 1.26 12.2 14.1 14.9
Capex / Sales 0.4% 0.43% 0.73% 0.31% 0.07% 0.61% 0.65% 0.66%
Announcement Date 08/04/20 31/03/21 29/03/22 30/03/23 27/03/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.14 EUR
Average target price
32 EUR
Spread / Average Target
+98.27%
Consensus